2 active not recruiting, 1 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Bladder Small Cell Neuroendocrine Carcinoma: new trials by email Literature Review of Bladder Small Cell Neuroendocrine Carcinoma trials Research Report on Bladder Small Cell Neuroendocrine Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-11-04 |
| Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Carboplatin, Cisplatin, Docetaxel - Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 15 | 2019-01-11 | 2025-11-12 |
| Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 152 | 2015-07-22 | 2026-10-15 |
Urethral Neoplasms (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Renal Cell (2) · Carcinoma, Transitional Cell (2) · Penile Neoplasms (2) · Prostatic Neoplasms (2) · Urogenital Neoplasms (2) · Urachal adenocarcinoma (1) · Ureteral Neoplasms (1)
Carcinoma (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Male (3) · Genital Neoplasms, Male (3) · Male Urogenital Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Urethral Diseases (3) · Urinary Bladder Diseases (3) · Urogenital Diseases (3) · Urologic Diseases (3)
CTLA-4 Antigen (2) · Ipilimumab (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Specimen Handling (2) · cabozantinib (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Biopsy (1) · Carboplatin (1) · Cisplatin (1) · Docetaxel (1) · Etoposide (1) · Platinum (1) · pembrolizumab (1)
National Cancer Institute (NCI) (2) · Jonsson Comprehensive Cancer Center (1)
United States (3) · Puerto Rico (1)
Andrea B Apolo (2) · Arnold Chin (1)
PMID 35031545, PMID 32915679, PMID 38954785, PMID 39536751
U10CA180821 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1), ZIABC011078 (1)